1. School of Pharmacy, College of Medicine, National Taiwan University, Taipei 100, Taiwan;2. Institute of Biotechnology and Pharmaceutical Research, National Health Research Institute, Miaoli County 35053, Taiwan
Abstract:
Novel C-aryl-d-glucofuranosides were synthesized and evaluated for their capacity to inhibit human sodium-dependent glucose co-transporter 2 (hSGLT2) and hSGLT1. Compound 21q demonstrated the best in vitro inhibitory activity against SGLT2 in this series (EC50 = 0.62 μM).